Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Mineral named after UFS professor
2017-09-29

Description: Mineral tredoux Tags: International Mineralogical Association, tredouxite, Prof Marian Tredoux, Department of Geology, Barberton 

Tredouxite (white) intergrown with bottinoite (light grey),
a complex hydrous alteration product. The large host
minerals are nickel-rich silicate (grey), maybe willemseite,
and the spinel trevorite (dark grey).


More than five thousand minerals have been certified by the International Mineralogical Association (IMA). One of these minerals, tredouxite, was recently named after an academic at the University of the Free State (UFS). 

Tredouxite was named after Prof Marian Tredoux, an associate professor in the Department of Geology, to acknowledge her close to 30 years’ commitment to figuring out the geological history of the rock in which this mineral occurs. The name was chosen by the team which identified the new mineral, consisting of Dr Federica Zaccarini and Prof. Giorgio Garuti from the University of Leoben, Austria, Prof. Luca Bindi from the University of Florence, Italy, and Prof. Duncan Miller from the UFS. 

They found the mineral in the abovementioned rock from the Barberton region in Mpumalanga, in May 2017.

In the past, a mineral was also named after Marie Curie
With the exception of a few historical (pre-1800) names, a mineral is typically named either after the area where it was first found, or after its chemical composition or physical properties, or after a person. If named after a person, it has to be someone who had nothing to do with finding the mineral.

Prof Tredoux said: “As of 19 September 2017, 5292 minerals had been certified by IMA. Of these, 81 were named after women, either singly or with a near relation. Marie Curie is named twice: sklodowskite (herself) and curite (plus husband). Most of the named women are Russian geoscientists.”

Another way to assess the rarity of such a naming is to consider that fewer than 700 minerals have been named after people. Given that there are by now seven billion people on the planet, it means that a person who is granted a mineral name becomes one in 10 million of the people alive today to be honoured in such a way. To date, over a dozen minerals had been named after South Africans, three of them after women (including tredouxite).

It contains nickel, antimony and oxygen
The chemical composition of tredouxite is NiSb2O6 (nickel antimony oxide). This makes it the nickel equivalent of the magnesium mineral bystromite (MgSb2O6), described in the 1950s from the La Fortuna antimony mine in Mexico.  

“This announcement is of great academic importance: the discovery by the Italian team of a phase with that specific chemical composition will undoubtedly help me and my co-workers to better understand the origin of the rock itself,” she said. She also expressed the hope that it may raise interest in the Department of Geology and the UFS as a whole, by highlighting that world-class research is being done at the department. 

The announcement of this new mineral was published on the International Mineralogical Association Commission on New Minerals, Nomenclature and Classification website, the Mineralogical Magazine and the European Journal of Mineralogy.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept